DTC Programmatic for Pharma: Where It Fits in the Plan

Programmatic in DTC pharma tends to get either too much credit or too little. Some plans treat it as a cheap reach filler; others expect it to do precise patient targeting it cannot legally or technically deliver anymore. The useful view sits in between. This article covers where programmatic belongs in the plan. For the hands-on setup (line items, deal IDs, QA), see the existing guide to DTC programmatic activation.

What DTC programmatic means in practice

Programmatic is a way of buying, not a channel. In a DTC plan it usually covers:

• CTV and streaming bought through a DSP, direct deals, or PMPs
• Online video across the open web and some video platforms
• Display, including rich media with scrolling ISI
• Audio and digital out-of-home in some plans

What these share is decisioning at the impression level, which allows targeting, frequency control, and reporting that traditional buys cannot match. That is also what brings the privacy questions.

The roles programmatic plays in a DTC plan

Audience vs. contextual buying

The audience versus contextual decision drives most of the programmatic plan. Condition audiences can concentrate spend, but sensitive conditions generally need opt-in consent under NAI rules, state laws such as Washington's My Health My Data Act add requirements, and many segments are more modeled than their names suggest. Contextual avoids most of that and does not depend on identifiers. The privacy detail is in condition and ailment audience targeting, and the side-by-side comparison is in contextual vs. audience targeting for DTC pharma.

Sequencing is the other place programmatic earns its keep. A household that saw the 60-second CTV spot can get a shorter online video or display unit a few days later, with a different message: what to ask the doctor, how the savings program works, where to find support. This works at the household or contextual level without building a condition audience, as long as the exposure data comes from your own buys and your legal team is comfortable with the setup. Keep the sequence short, two or three steps, and test it against a group that only saw the first spot.

I would start most sensitive-condition plans with contextual as the base and add audiences only where the consent story is clean and a test shows they add something.

CTV inside programmatic

CTV is usually the biggest programmatic line in a DTC plan now. Programmatic CTV lets you target at the household level, cap frequency across apps, and match exposure to outcomes. It also brings resold supply, app-level opacity, and device graph issues. Ask for app-level reporting, buy mostly through direct and PMP paths, and plan CTV and linear together to deduplicated reach. Frequency is covered in CTV frequency management for pharma.

Retargeting limits

Retargeting is the area where pharma programmatic differs most from consumer retail. A visitor to a brand site for an HIV or depression treatment has, by visiting, revealed something about their health. Using that visit to follow them around the web can be treated as creating consumer health data without consent. Many legal teams prohibit it for sensitive conditions and restrict it elsewhere.

Where retargeting is allowed, practical limits help: short lookback windows, low frequency, no retargeting from pages that indicate diagnosis (symptom checkers, savings card forms), and exclusion of states your legal team flags. Brand site pixels also need governance; see tracking pixel governance on pharma websites.

Supply quality is part of the strategy

Cheap programmatic reach is often low quality reach. Made-for-advertising sites, resold CTV, and long supply paths take a share of the budget that never reaches a real person. The ANA's programmatic transparency work has documented how much of open web spend goes to low quality inventory and intermediaries. Use ads.txt and sellers.json checks, inclusion lists, and a deliberate supply path; the supply path optimization guide for pharma covers what to remove.

How to judge whether DTC programmatic is working

1. Deduplicated reach. Did programmatic add households that TV missed, or just add frequency to the same ones?
2. Quality-adjusted delivery. Viewable, human, in-geo impressions on suitable content.
3. Qualified site actions. Discussion guide downloads and savings card activations, not just clicks.
4. Incremental outcomes. New-to-brand prescriptions against a holdout or matched comparison.

Click-through rate is the metric that misleads most often. It rewards accidental clicks, mobile in-app placements, and broad segments, which is the opposite of what a pharma plan needs.

Practical takeaway

Pull a report of your last quarter's DTC programmatic spend by role (reach extension, contextual, audience, sequencing, retargeting). If more than a small share is in retargeting or unnamed open exchange supply, move it to contextual or direct CTV and set up a holdout so the next quarter's read is incremental.

Frequently asked questions

What is DTC programmatic in pharma?

It is the automated buying of consumer-facing ad inventory (display, video, CTV, audio, and digital out-of-home) for a pharma brand through DSPs and private marketplaces. It usually extends TV reach, delivers contextual health placements, and sequences messages after video exposure.

Can pharma brands retarget website visitors?

It depends on the condition, the consent obtained on the site, and state law. For sensitive conditions, retargeting brand site visitors can amount to building a health audience without consent, and many legal teams prohibit it. Where allowed, keep windows short and frequency low.

Is CTV part of DTC programmatic?

Often yes. Much CTV inventory is bought programmatically through DSPs, direct deals, or PMPs, which allows household-level targeting and frequency control across apps. Some CTV is still bought through direct publisher insertion orders.

Sources

• IAB Tech Lab, ads.txt
• IAB Tech Lab, sellers.json
• Network Advertising Initiative
• ANA, Programmatic Media Supply Chain Transparency Study

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.